§ 213. Fraudulent representations to evade or defeat restrictions

No person, firm, or corporation whose permanent allegiance is due to the United States seeking to procure in the consular districts of the United States in China any substance the sale of which is regulated by the provisions of this chapter shall make any fraudulent representations so as to evade or defeat the restrictions herein imposed.

(Mar. 3, 1915, ch. 74, §8, 38 Stat. 821.)

§214. Previous laws unaffected

Nothing in this chapter shall be construed as modifying or revoking any of the provisions of sections 191 to 1931 of this title.

(Mar. 3, 1915, ch. 74, §13, 38 Stat. 822.)

Editorial Notes

References in Text

Sections 191 to 193 of this title, referred to in text, were repealed by Pub. L. 91-513, title III, §1101(a)(1), Oct. 27, 1970, 84 Stat. 1291. See section 801 et seq. of this

§ 215. "Consul" defined

The word "consul" as used in this chapter shall mean the consular officer in charge of the district concerned.

(Mar. 3, 1915, ch. 74, §12, 38 Stat. 822.)

CHAPTER 8-NARCOTIC FARMS

§§ 221 to 237. Repealed. July 1, 1944, ch. 373, title XIII, § 1313, 58 Stat. 714

Section 221, act Jan. 19, 1929, ch. 82, \$1, 45 Stat. 1085, defined "habit-forming narcotic drug", "narcotic", and "addict". See section 201 of Title 42, The Public Health and Welfare.

Section 222, act Jan. 19, 1929, ch. 82, §2, 45 Stat. 1085, provided for narcotic farms.

Section 222a, act June 23, 1935, ch. 725, §1, 49 Stat. 1840, provided name for narcotic farm at Lexington, Ky. Section 222b, act Mar. 28, 1938, ch. 55, §1, 52 Stat. 134, provided name for narcotic farm at Fort Worth, Texas.

Section 223, act Jan. 19, 1929, ch. 82, §3, 45 Stat. 1085; 1939 Reorg. Plan No. I, $\S205(b)$, eff. July 1, 1939, 4 F.R. 2728, 53 Stat. 1425, provided for an annual estimate of expenses of maintenance of narcotic farms.

Section 224, act Jan. 19, 1929, ch. 82, §4, 45 Stat. 1086, provided for construction of buildings for two of the narcotic farms.

Section 225, acts Jan. 19, 1929, ch. 82, §5, 45 Stat. 1086; June 14, 1930, ch. 488, §4(a), 46 Stat. 586; 1939 Reorg. Plan No. I, §§ 201, 205, eff. July 1, 1939, 4 F.R. 2728, 53 Stat. 1424, provided for control and management of narcotic farms.

Section 226, act Jan. 19, 1929, ch. 82, §6, 45 Stat. 1086; 1939 Reorg. Plan No. I, §§ 201, 205, eff. July 1, 1939, 4 F.R. 2728, 53 Stat. 1424, 1425, provided for care and treatment of addicts.

Section 227, act Jan. 19, 1929, ch. 82, §7, 45 Stat. 1086, provided for transfer to and from farms of addicts who

Section 228, act Jan. 19, 1929, ch. 82, §8, 45 Stat. 1087, provided that it was the duty of prosecuting officers to report convicted persons believed to be addicts.

Section 229, act Jan. 19, 1929, ch. 82, §9, 45 Stat. 1087; 1939 Reorg. Plan No. I, §§ 201, 205, eff. July 1, 1939, 4 F.R.

Section 230, act Jan. 19, 1929, ch. 82, §10, 45 Stat. 1087, provided for parole of inmates.

Section 231, act Jan. 19, 1929, ch. 82, §11, 45 Stat. 1087; 1939 Reorg. Plan No. I, §§ 201, 205, eff. July 1, 1939, 4 F.R. 2728, 53 Stat. 1424, 1425, provided for discharge of addicts.

Section 232, act Jan. 19, 1929, ch. 82, §12, 45 Stat. 1088; 1939 Reorg. Plan No. I, §§ 201, 205, eff. July 1, 1939, 4 F.R. 2728, 53 Stat. 1424, 1425, provided for admission of voluntary patients.

Section 233, act Jan. 19, 1929, ch. 82, §13, 45 Stat. 1088; 1939 Reorg. Plan No. I, §§ 201, 205, eff. July 1, 1939, 4 F.R. 2728, 53 Stat. 1424, 1425, provided for furnishing of gratuities and transportation to discharged convicts.

Section 234, act. Jan. 19, 1929, ch. 82, §14, 45 Stat. 1089; 1939 Reorg. Plan No. I, §§ 201, 205, eff. July 1, 1939, 4 F.R. 2728, 53 Stat. 1424, 1425, provided penalties for introduction of narcotic drugs into a narcotic farm.

Section 235, act Jan. 19, 1929, ch. 82, §15, 45 Stat. 1089, provided penalties for escape of inmates.

Section 236, act Jan. 19, 1929, ch. 82, §16, 45 Stat. 1089, provided penalties for procuring of escape by inmates.

Section 237, act Jan. 19, 1929, ch. 82, §17, 45 Stat. 1089, provided for deportation of alien inmates who are entitled to a discharge from narcotic farms.

Editorial Notes

RENUMBERING OF REPEALING ACT

Title XIII, §1313, formerly title VI, §611, of act July 1, 1944, which repealed these sections, was renumbered title VII, §711, by act Aug. 13, 1946, ch. 958, §5, 60 Stat. 1049; §713, by act Feb. 28, 1948, ch. 83, §9(b), 62 Stat. 47; title VIII, §813, by act July 30, 1956, ch. 779, §3(b), 70 Stat. 721; title IX, §913, by Pub. L. 88-581, §4(b), Sept. 4, 1964, 78 Stat. 919; title X, §1013, by Pub. L. 89-239, §3(b), Oct. 6, 1965, 79 Stat. 931; title XI, §1113, by Pub. L. 91-572, §6(b), Dec. 24, 1970, 84 Stat. 1506; title XII, §1213, by Pub. L. 92-294, §3(b), May 16, 1972, 86 Stat. 137; title XIII, §1313, by Pub. L. 93–154, §2(b)(2), Nov. 16, 1973, 87 Stat. 604, and was repealed by Pub. L. 93–222, §7(b), Dec. 29, 1973, 87 Stat. 936.

CHAPTER 9-FEDERAL FOOD, DRUG, AND COSMETIC ACT

SUBCHAPTER I—SHORT TITLE

Sec. 301. Short title.

SUBCHAPTER II—DEFINITIONS

321. Definitions; generally. 321a. "Butter" defined. 321b. "Package" defined.

321c. Nonfat dry milk; "milk" defined.

321d. Market names for catfish and ginseng.

SUBCHAPTER III—PROHIBITED ACTS AND PENALTIES

Prohibited acts. 331. 332.

Injunction proceedings.

333. Penalties.

333a. Repealed.

334. Seizure.

335. Hearing before report of criminal violation. 335a.

Debarment, temporary denial of approval,

and suspension.

335b. Civil penalties.

Authority to withdraw approval of abbre-335c. viated drug applications.

336. Report of minor violations.

337.Proceedings in name of United States; provision as to subpoenas.

337a. Extraterritorial jurisdiction.

SUBCHAPTER IV-FOOD

Definitions and standards for food. 341

^{2728, 53} Stat. 1424, 1425, provided for employment of ad-

¹ See References in Text note below.

		Sec.	
342.	Adulterated food.	356c-1.	Annual reporting on drug shortages.
343.	Misbranded food.	356d.	Coordination; task force and strategic plan.
343-1.	National uniform nutrition labeling.	356e.	Drug shortage list.
343–2.	Dietary supplement labeling exemptions.	356f.	Hospital repackaging of drugs in shortage.
343–3.	Disclosure.	356g.	Standards for regenerative medicine and re-
343a.	Repealed.	0.501	generative advanced therapies.
344. 345.	Emergency permit control. Regulations making exemptions.	356h.	Competitive generic therapies.
345. 346.	Tolerances for poisonous or deleterious sub-	356i.	Prompt reports of marketing status.
540.	stances in food; regulations.	356j.	Discontinuance or interruption in the produc-
346a.	Tolerances and exemptions for pesticide	057	tion of medical devices.
0.1000.	chemical residues.	357. 358.	Qualification of drug development tools. Authority to designate official names.
346b.	Authorization of appropriations.	359.	Nonapplicability of subchapter to cosmetics.
347.	Intrastate sales of colored oleomargarine.	360.	Registration of producers of drugs or devices.
347a.	Congressional declaration of policy regarding	360a.	Clinical trial guidance for antibiotic drugs.
	oleomargarine sales.	360a-1.	Clinical trials.
347b.	Contravention of State laws.	360a-2.	Susceptibility test interpretive criteria for
348.	Food additives.	00000 2.	microorganisms.
349.	Bottled drinking water standards; publication	360b.	New animal drugs.
	in Federal Register.	360b-1.	Priority zoonotic animal drugs.
350.	Vitamins and minerals.	360c.	Classification of devices intended for human
350a.	Infant formulas.		use.
350b.	New dietary ingredients.	360c-1.	Reporting.
350c.	Maintenance and inspection of records. Registration of food facilities.	360d.	Performance standards.
350d. 350e.	Sanitary transportation practices.	360e.	Premarket approval.
350e. 350f.	Reportable food registry.	$360e{-1}$.	Pediatric uses of devices.
350g.	Hazard analysis and risk-based preventive	360e-3.	Breakthrough devices.
550g.	controls.	360f.	Banned devices.
350h.	Standards for produce safety.	360g.	Judicial review.
350i.	Protection against intentional adulteration.	360g-1.	Agency documentation and review of signifi-
350j.	Targeting of inspection resources for domes-		cant decisions regarding devices.
0003.	tic facilities, foreign facilities, and ports of	360h.	Notification and other remedies.
	entry; annual report.	360h-1.	Program to improve the device recall system.
350k.	Laboratory accreditation for analyses of	360i.	Records and reports on devices.
	foods.	360j.	General provisions respecting control of de-
350l.	Mandatory recall authority.	0001-	vices intended for human use.
350l-1.	Annual report to Congress.	360k.	State and local requirements respecting devices.
SI	JBCHAPTER V—DRUGS AND DEVICES	360 <i>l</i> .	Postmarket surveillance.
		360m.	Accredited persons.
	PART A—DRUGS AND DEVICES	360n.	Priority review to encourage treatments for
351.	Adulterated drugs and devices.	50011.	tropical diseases.
352.	Misbranded drugs and devices.	360n-1.	Priority review for qualified infectious dis-
353.	Exemptions and consideration for certain	00011 1.	ease products.
	A A A		
	drugs, devices, and biological products.		-
353a.	Pharmacy compounding.	PART	B—Drugs for Rare Diseases or Conditions
353a-1.	Pharmacy compounding. Enhanced communication.		B—Drugs for Rare Diseases or Conditions
353a-1. 353b.	Pharmacy compounding. Enhanced communication. Outsourcing facilities.	PART 360aa.	B—Drugs for Rare Diseases or Conditions Recommendations for investigations of drugs
353a–1. 353b. 353c.	Pharmacy compounding. Enhanced communication. Outsourcing facilities. Prereview of television advertisements.		B—Drugs for Rare Diseases or Conditions Recommendations for investigations of drugs for rare diseases or conditions.
353a-1. 353b.	Pharmacy compounding. Enhanced communication. Outsourcing facilities. Prereview of television advertisements. Process to update labeling for certain generic	360aa.	B—Drugs for Rare Diseases or Conditions Recommendations for investigations of drugs
353a–1. 353b. 353c. 353d.	Pharmacy compounding. Enhanced communication. Outsourcing facilities. Prereview of television advertisements. Process to update labeling for certain generic drugs.	360aa.	B—Drugs for Rare Diseases or Conditions Recommendations for investigations of drugs for rare diseases or conditions. Designation of drugs for rare diseases or conditions.
353a-1. 353b. 353c. 353d.	Pharmacy compounding. Enhanced communication. Outsourcing facilities. Prereview of television advertisements. Process to update labeling for certain generic drugs. Veterinary feed directive drugs.	360aa. 360bb.	B—Drugs for Rare Diseases or Conditions Recommendations for investigations of drugs for rare diseases or conditions. Designation of drugs for rare diseases or con-
353a–1. 353b. 353c. 353d. 354. 355.	Pharmacy compounding. Enhanced communication. Outsourcing facilities. Prereview of television advertisements. Process to update labeling for certain generic drugs. Veterinary feed directive drugs. New drugs.	360aa. 360bb.	B—Drugs for Rare Diseases or Conditions Recommendations for investigations of drugs for rare diseases or conditions. Designation of drugs for rare diseases or conditions. Protection for drugs for rare diseases or con-
353a–1. 353b. 353c. 353d. 354. 355. 355–1.	Pharmacy compounding. Enhanced communication. Outsourcing facilities. Prereview of television advertisements. Process to update labeling for certain generic drugs. Veterinary feed directive drugs. New drugs. Risk evaluation and mitigation strategies.	360aa. 360bb. 360cc. 360dd.	B—Drugs for Rare Diseases or Conditions Recommendations for investigations of drugs for rare diseases or conditions. Designation of drugs for rare diseases or conditions. Protection for drugs for rare diseases or conditions.
353a–1. 353b. 353c. 353d. 354. 355.	Pharmacy compounding. Enhanced communication. Outsourcing facilities. Prereview of television advertisements. Process to update labeling for certain generic drugs. Veterinary feed directive drugs. New drugs. Risk evaluation and mitigation strategies. Actions for delays of generic drugs and bio-	360aa. 360bb. 360cc.	B—Drugs for Rare Diseases or Conditions Recommendations for investigations of drugs for rare diseases or conditions. Designation of drugs for rare diseases or conditions. Protection for drugs for rare diseases or conditions. Open protocols for investigations of drugs for rare diseases or conditions. Grants and contracts for development of
353a-1. 353b. 353c. 353d. 354. 355. 355-1. 355-2.	Pharmacy compounding. Enhanced communication. Outsourcing facilities. Prereview of television advertisements. Process to update labeling for certain generic drugs. Veterinary feed directive drugs. New drugs. Risk evaluation and mitigation strategies. Actions for delays of generic drugs and biosimilar biological products.	360aa. 360bb. 360cc. 360dd. 360ee.	B—Drugs for Rare Diseases or Conditions Recommendations for investigations of drugs for rare diseases or conditions. Designation of drugs for rare diseases or conditions. Protection for drugs for rare diseases or conditions. Open protocols for investigations of drugs for rare diseases or conditions. Grants and contracts for development of drugs for rare diseases and conditions.
353a-1. 353b. 353c. 353d. 354. 355. 355-1. 355-2. 355a.	Pharmacy compounding. Enhanced communication. Outsourcing facilities. Prereview of television advertisements. Process to update labeling for certain generic drugs. Veterinary feed directive drugs. New drugs. Risk evaluation and mitigation strategies. Actions for delays of generic drugs and biosimilar biological products. Pediatric studies of drugs.	360aa. 360bb. 360cc. 360dd.	B—Drugs for Rare Diseases or Conditions Recommendations for investigations of drugs for rare diseases or conditions. Designation of drugs for rare diseases or conditions. Protection for drugs for rare diseases or conditions. Open protocols for investigations of drugs for rare diseases or conditions. Grants and contracts for development of drugs for rare diseases and conditions. Priority review to encourage treatments for
353a-1. 353b. 353c. 353d. 354. 355. 355-1. 355-2. 355a. 355b.	Pharmacy compounding. Enhanced communication. Outsourcing facilities. Prereview of television advertisements. Process to update labeling for certain generic drugs. Veterinary feed directive drugs. New drugs. Risk evaluation and mitigation strategies. Actions for delays of generic drugs and biosimilar biological products. Pediatric studies of drugs. Adverse-event reporting.	360aa. 360bb. 360cc. 360dd. 360ee. 360ff.	B—Drugs for Rare Diseases or Conditions Recommendations for investigations of drugs for rare diseases or conditions. Designation of drugs for rare diseases or conditions. Protection for drugs for rare diseases or conditions. Open protocols for investigations of drugs for rare diseases or conditions. Grants and contracts for development of drugs for rare diseases and conditions. Priority review to encourage treatments for rare pediatric diseases.
353a-1. 353b. 353c. 353d. 354. 355. 355-1. 355-2. 355a.	Pharmacy compounding. Enhanced communication. Outsourcing facilities. Prereview of television advertisements. Process to update labeling for certain generic drugs. Veterinary feed directive drugs. New drugs. Risk evaluation and mitigation strategies. Actions for delays of generic drugs and biosimilar biological products. Pediatric studies of drugs. Adverse-event reporting. Research into pediatric uses for drugs and bi-	360aa. 360bb. 360cc. 360dd. 360ee.	B—Drugs for Rare Diseases or Conditions Recommendations for investigations of drugs for rare diseases or conditions. Designation of drugs for rare diseases or conditions. Protection for drugs for rare diseases or conditions. Open protocols for investigations of drugs for rare diseases or conditions. Grants and contracts for development of drugs for rare diseases and conditions. Priority review to encourage treatments for
353a-1. 353b. 353c. 353d. 354. 355. 355-1. 355-2. 355a. 355b.	Pharmacy compounding. Enhanced communication. Outsourcing facilities. Prereview of television advertisements. Process to update labeling for certain generic drugs. Veterinary feed directive drugs. New drugs. Risk evaluation and mitigation strategies. Actions for delays of generic drugs and biosimilar biological products. Pediatric studies of drugs. Adverse-event reporting. Research into pediatric uses for drugs and biological products.	360aa. 360bb. 360cc. 360dd. 360ee. 360ff.	B—Drugs for Rare Diseases or Conditions Recommendations for investigations of drugs for rare diseases or conditions. Designation of drugs for rare diseases or conditions. Protection for drugs for rare diseases or conditions. Open protocols for investigations of drugs for rare diseases or conditions. Grants and contracts for development of drugs for rare diseases and conditions. Priority review to encourage treatments for rare pediatric diseases. Targeted drugs for rare diseases.
353a-1. 353b. 353c. 353d. 354. 355-1. 355-2. 355a. 355b. 355c.	Pharmacy compounding. Enhanced communication. Outsourcing facilities. Prereview of television advertisements. Process to update labeling for certain generic drugs. Veterinary feed directive drugs. New drugs. Risk evaluation and mitigation strategies. Actions for delays of generic drugs and biosimilar biological products. Pediatric studies of drugs. Adverse-event reporting. Research into pediatric uses for drugs and bi-	360aa. 360bb. 360cc. 360dd. 360ee. 360ff. PART	B—Drugs for Rare Diseases or Conditions Recommendations for investigations of drugs for rare diseases or conditions. Designation of drugs for rare diseases or conditions. Protection for drugs for rare diseases or conditions. Open protocols for investigations of drugs for rare diseases or conditions. Grants and contracts for development of drugs for rare diseases and conditions. Priority review to encourage treatments for rare pediatric diseases. Targeted drugs for rare diseases. C—ELECTRONIC PRODUCT RADIATION CONTROL
353a-1. 353b. 353c. 353d. 354. 355. 355-1. 355-2. 355a. 355b. 355c.	Pharmacy compounding. Enhanced communication. Outsourcing facilities. Prereview of television advertisements. Process to update labeling for certain generic drugs. Veterinary feed directive drugs. New drugs. Risk evaluation and mitigation strategies. Actions for delays of generic drugs and biosimilar biological products. Pediatric studies of drugs. Adverse-event reporting. Research into pediatric uses for drugs and biological products. Report.	360aa. 360bb. 360cc. 360dd. 360ee. 360ff. 360ff-1. PART 360hh.	B—Drugs for Rare Diseases or Conditions Recommendations for investigations of drugs for rare diseases or conditions. Designation of drugs for rare diseases or conditions. Protection for drugs for rare diseases or conditions. Open protocols for investigations of drugs for rare diseases or conditions. Grants and contracts for development of drugs for rare diseases and conditions. Priority review to encourage treatments for rare pediatric diseases. Targeted drugs for rare diseases. C—ELECTRONIC PRODUCT RADIATION CONTROL Definitions.
353a-1. 353b. 353c. 353d. 354. 355. 355-1. 355-2. 355a. 355b. 355c.	Pharmacy compounding. Enhanced communication. Outsourcing facilities. Prereview of television advertisements. Process to update labeling for certain generic drugs. Veterinary feed directive drugs. New drugs. Risk evaluation and mitigation strategies. Actions for delays of generic drugs and biosimilar biological products. Pediatric studies of drugs. Adverse-event reporting. Research into pediatric uses for drugs and biological products. Report. Internal committee for review of pediatric	360aa. 360bb. 360cc. 360dd. 360ee. 360ff. 360ff-1. PART 360hh. 360ii.	B—Drugs for Rare Diseases or Conditions Recommendations for investigations of drugs for rare diseases or conditions. Designation of drugs for rare diseases or conditions. Protection for drugs for rare diseases or conditions. Open protocols for investigations of drugs for rare diseases or conditions. Grants and contracts for development of drugs for rare diseases and conditions. Priority review to encourage treatments for rare pediatric diseases. Targeted drugs for rare diseases. C—ELECTRONIC PRODUCT RADIATION CONTROL Definitions. Program of control.
353a-1. 353b. 353c. 353d. 354. 355. 355-1. 355-2. 355a. 355b. 355c.	Pharmacy compounding. Enhanced communication. Outsourcing facilities. Prereview of television advertisements. Process to update labeling for certain generic drugs. Veterinary feed directive drugs. New drugs. Risk evaluation and mitigation strategies. Actions for delays of generic drugs and biosimilar biological products. Pediatric studies of drugs. Adverse-event reporting. Research into pediatric uses for drugs and biological products. Report. Internal committee for review of pediatric plans, assessments, deferrals, deferral ex-	360aa. 360bb. 360cc. 360dd. 360ee. 360ff. 360ff-1. PART 360hh. 360ii. 360jj.	B—Drugs for Rare Diseases or Conditions Recommendations for investigations of drugs for rare diseases or conditions. Designation of drugs for rare diseases or conditions. Protection for drugs for rare diseases or conditions. Open protocols for investigations of drugs for rare diseases or conditions. Grants and contracts for development of drugs for rare diseases and conditions. Priority review to encourage treatments for rare pediatric diseases. Targeted drugs for rare diseases. C—ELECTRONIC PRODUCT RADIATION CONTROL Definitions. Program of control. Studies by Secretary.
353a-1. 353b. 353c. 353d. 354. 355. 355-1. 355-2. 355a. 355b. 355c. 355c-1. 355d.	Pharmacy compounding. Enhanced communication. Outsourcing facilities. Prereview of television advertisements. Process to update labeling for certain generic drugs. Veterinary feed directive drugs. New drugs. Risk evaluation and mitigation strategies. Actions for delays of generic drugs and biosimilar biological products. Pediatric studies of drugs. Adverse-event reporting. Research into pediatric uses for drugs and biological products. Report. Internal committee for review of pediatric plans, assessments, deferrals, deferral extensions, and waivers. Pharmaceutical security. Extension of exclusivity period for new quali-	360aa. 360bb. 360cc. 360dd. 360ee. 360ff. 360ff-1. PART 360hh. 360ii.	B—Drugs for Rare Diseases or Conditions Recommendations for investigations of drugs for rare diseases or conditions. Designation of drugs for rare diseases or conditions. Protection for drugs for rare diseases or conditions. Open protocols for investigations of drugs for rare diseases or conditions. Grants and contracts for development of drugs for rare diseases and conditions. Priority review to encourage treatments for rare pediatric diseases. Targeted drugs for rare diseases. C—Electronic Product Radiation Control Definitions. Program of control. Studies by Secretary. Performance standards for electronic prod-
353a-1. 353b. 353c. 353d. 354. 355. 355-1. 355-2. 355a. 355b. 355c. 355c-1. 355d.	Pharmacy compounding. Enhanced communication. Outsourcing facilities. Prereview of television advertisements. Process to update labeling for certain generic drugs. Veterinary feed directive drugs. New drugs. Risk evaluation and mitigation strategies. Actions for delays of generic drugs and biosimilar biological products. Pediatric studies of drugs. Adverse-event reporting. Research into pediatric uses for drugs and biological products. Report. Internal committee for review of pediatric plans, assessments, deferrals, deferral extensions, and waivers. Pharmaceutical security. Extension of exclusivity period for new qualified infectious disease products.	360aa. 360bb. 360cc. 360dd. 360ec. 360ff. 360ff-1. PART 360hh. 360jj. 360kk.	B—Drugs for Rare Diseases or Conditions Recommendations for investigations of drugs for rare diseases or conditions. Designation of drugs for rare diseases or conditions. Protection for drugs for rare diseases or conditions. Open protocols for investigations of drugs for rare diseases or conditions. Grants and contracts for development of drugs for rare diseases and conditions. Priority review to encourage treatments for rare pediatric diseases. Targeted drugs for rare diseases. C—ELECTRONIC PRODUCT RADIATION CONTROL Definitions. Program of control. Studies by Secretary. Performance standards for electronic products.
353a-1. 353b. 353c. 353d. 354. 355-1. 355-2. 355a. 355b. 355c. 355c-1. 355d. 355e. 355e. 355e.	Pharmacy compounding. Enhanced communication. Outsourcing facilities. Prereview of television advertisements. Process to update labeling for certain generic drugs. Veterinary feed directive drugs. New drugs. Risk evaluation and mitigation strategies. Actions for delays of generic drugs and biosimilar biological products. Pediatric studies of drugs. Adverse-event reporting. Research into pediatric uses for drugs and biological products. Report. Internal committee for review of pediatric plans, assessments, deferrals, deferral extensions, and waivers. Pharmaceutical security. Extension of exclusivity period for new qualified infectious disease products. Utilizing real world evidence.	360aa. 360bb. 360cc. 360dd. 360ee. 360ff. 360ff-1. PART 360hh. 360ii. 360jj.	B—Drugs for Rare Diseases or Conditions Recommendations for investigations of drugs for rare diseases or conditions. Designation of drugs for rare diseases or conditions. Protection for drugs for rare diseases or conditions. Open protocols for investigations of drugs for rare diseases or conditions. Grants and contracts for development of drugs for rare diseases and conditions. Priority review to encourage treatments for rare pediatric diseases. Targeted drugs for rare diseases. C—Electronic Product Radiation Control Definitions. Program of control. Studies by Secretary. Performance standards for electronic products. Notification of defects in and repair or re-
353a-1. 353b. 353c. 353d. 354. 355. 355-1. 355-2. 355a. 355b. 355c. 355c-1. 355d.	Pharmacy compounding. Enhanced communication. Outsourcing facilities. Prereview of television advertisements. Process to update labeling for certain generic drugs. Veterinary feed directive drugs. New drugs. Risk evaluation and mitigation strategies. Actions for delays of generic drugs and biosimilar biological products. Pediatric studies of drugs. Adverse-event reporting. Research into pediatric uses for drugs and biological products. Report. Internal committee for review of pediatric plans, assessments, deferrals, deferral extensions, and waivers. Pharmaceutical security. Extension of exclusivity period for new qualified infectious disease products. Utilizing real world evidence. Regulation of certain nonprescription drugs	360aa. 360bb. 360cc. 360dd. 360ee. 360ff. 360ff-1. PART 360hh. 360jj. 360kk.	B—Drugs for Rare Diseases or Conditions Recommendations for investigations of drugs for rare diseases or conditions. Designation of drugs for rare diseases or conditions. Protection for drugs for rare diseases or conditions. Open protocols for investigations of drugs for rare diseases or conditions. Grants and contracts for development of drugs for rare diseases and conditions. Priority review to encourage treatments for rare pediatric diseases. Targeted drugs for rare diseases. C—ELECTRONIC PRODUCT RADIATION CONTROL Definitions. Program of control. Studies by Secretary. Performance standards for electronic products. Notification of defects in and repair or replacement of electronic products.
353a-1. 353b. 353c. 353d. 354. 355-1. 355-2. 355a. 355b. 355c. 355c-1. 355d. 355e. 355e. 355e.	Pharmacy compounding. Enhanced communication. Outsourcing facilities. Prereview of television advertisements. Process to update labeling for certain generic drugs. Veterinary feed directive drugs. New drugs. Risk evaluation and mitigation strategies. Actions for delays of generic drugs and biosimilar biological products. Pediatric studies of drugs. Adverse-event reporting. Research into pediatric uses for drugs and biological products. Report. Internal committee for review of pediatric plans, assessments, deferrals, deferral extensions, and waivers. Pharmaceutical security. Extension of exclusivity period for new qualified infectious disease products. Utilizing real world evidence. Regulation of certain nonprescription drugs that are marketed without an approved	360aa. 360bb. 360cc. 360dd. 360ee. 360ff. 360ff-1. PART 360hh. 360jj. 360kk. 360 <i>ll</i> .	B—Drugs for Rare Diseases or Conditions Recommendations for investigations of drugs for rare diseases or conditions. Designation of drugs for rare diseases or conditions. Protection for drugs for rare diseases or conditions. Open protocols for investigations of drugs for rare diseases or conditions. Grants and contracts for development of drugs for rare diseases and conditions. Priority review to encourage treatments for rare pediatric diseases. Targeted drugs for rare diseases. C—ELECTRONIC PRODUCT RADIATION CONTROL Definitions. Program of control. Studies by Secretary. Performance standards for electronic products. Notification of defects in and repair or replacement of electronic products. Imports.
353a-1. 353b. 353c. 353d. 354. 355. 355-1. 355-2. 355a. 355b. 355c. 355c-1. 355d. 355c. 355f. 355f.	Pharmacy compounding. Enhanced communication. Outsourcing facilities. Prereview of television advertisements. Process to update labeling for certain generic drugs. Veterinary feed directive drugs. New drugs. Risk evaluation and mitigation strategies. Actions for delays of generic drugs and biosimilar biological products. Pediatric studies of drugs. Adverse-event reporting. Research into pediatric uses for drugs and biological products. Report. Internal committee for review of pediatric plans, assessments, deferrals, deferral extensions, and waivers. Pharmaceutical security. Extension of exclusivity period for new qualified infectious disease products. Utilizing real world evidence. Regulation of certain nonprescription drugs that are marketed without an approved drug application.	360aa. 360bb. 360cc. 360dd. 360ee. 360ff. 360ff-1. PART 360hh. 360jj. 360kk. 360ll. 360mm.	B—Drugs for Rare Diseases or Conditions Recommendations for investigations of drugs for rare diseases or conditions. Designation of drugs for rare diseases or conditions. Protection for drugs for rare diseases or conditions. Open protocols for investigations of drugs for rare diseases or conditions. Grants and contracts for development of drugs for rare diseases and conditions. Priority review to encourage treatments for rare pediatric diseases. Targeted drugs for rare diseases. C—ELECTRONIC PRODUCT RADIATION CONTROL Definitions. Program of control. Studies by Secretary. Performance standards for electronic products. Notification of defects in and repair or replacement of electronic products. Imports. Inspection, records, and reports.
353a-1. 353b. 353c. 353d. 354. 355-1. 355-2. 355a. 355b. 355c. 355c-1. 355d. 355e. 355e. 355e.	Pharmacy compounding. Enhanced communication. Outsourcing facilities. Prereview of television advertisements. Process to update labeling for certain generic drugs. Veterinary feed directive drugs. New drugs. Risk evaluation and mitigation strategies. Actions for delays of generic drugs and biosimilar biological products. Pediatric studies of drugs. Adverse-event reporting. Research into pediatric uses for drugs and biological products. Report. Internal committee for review of pediatric plans, assessments, deferrals, deferral extensions, and waivers. Pharmaceutical security. Extension of exclusivity period for new qualified infectious disease products. Utilizing real world evidence. Regulation of certain nonprescription drugs that are marketed without an approved drug application.	360aa. 360bb. 360cc. 360dd. 360ee. 360ff. 360ff-1. PART 360hh. 360ii. 360ij. 360kk. 360ll. 360mm. 360oo.	B—Drugs for Rare Diseases or Conditions Recommendations for investigations of drugs for rare diseases or conditions. Designation of drugs for rare diseases or conditions. Protection for drugs for rare diseases or conditions. Open protocols for investigations of drugs for rare diseases or conditions. Grants and contracts for development of drugs for rare diseases and conditions. Priority review to encourage treatments for rare pediatric diseases. Targeted drugs for rare diseases. C—ELECTRONIC PRODUCT RADIATION CONTROL Definitions. Program of control. Studies by Secretary. Performance standards for electronic products. Notification of defects in and repair or replacement of electronic products. Imports. Inspection, records, and reports. Prohibited acts.
353a-1. 353b. 353c. 353d. 354. 355. 355-1. 355-2. 355a. 355b. 355c. 355c-1. 355d. 355e. 355f. 355f. 355f.	Pharmacy compounding. Enhanced communication. Outsourcing facilities. Prereview of television advertisements. Process to update labeling for certain generic drugs. Veterinary feed directive drugs. New drugs. Risk evaluation and mitigation strategies. Actions for delays of generic drugs and biosimilar biological products. Pediatric studies of drugs. Adverse-event reporting. Research into pediatric uses for drugs and biological products. Report. Internal committee for review of pediatric plans, assessments, deferrals, deferral extensions, and waivers. Pharmaceutical security. Extension of exclusivity period for new qualified infectious disease products. Utilizing real world evidence. Regulation of certain nonprescription drugs that are marketed without an approved drug application. Expedited approval of drugs for serious or life-threatening diseases or conditions.	360aa. 360bb. 360cc. 360dd. 360ee. 360ff. 360ff-1. PART 360hh. 360jj. 360kk. 360ll. 360mm. 360oo. 360pp.	B—Drugs for Rare Diseases or Conditions Recommendations for investigations of drugs for rare diseases or conditions. Designation of drugs for rare diseases or conditions. Protection for drugs for rare diseases or conditions. Open protocols for investigations of drugs for rare diseases or conditions. Grants and contracts for development of drugs for rare diseases and conditions. Priority review to encourage treatments for rare pediatric diseases. Targeted drugs for rare diseases. C—ELECTRONIC PRODUCT RADIATION CONTROL Definitions. Program of control. Studies by Secretary. Performance standards for electronic products. Notification of defects in and repair or replacement of electronic products. Imports. Inspection, records, and reports. Prohibited acts. Enforcement.
353a-1. 353b. 353c. 353d. 354. 355. 355-1. 355-2. 355a. 355b. 355c. 355c-1. 355d. 355c. 355f. 355f.	Pharmacy compounding. Enhanced communication. Outsourcing facilities. Prereview of television advertisements. Process to update labeling for certain generic drugs. Veterinary feed directive drugs. New drugs. Risk evaluation and mitigation strategies. Actions for delays of generic drugs and biosimilar biological products. Pediatric studies of drugs. Adverse-event reporting. Research into pediatric uses for drugs and biological products. Report. Internal committee for review of pediatric plans, assessments, deferrals, deferral extensions, and waivers. Pharmaceutical security. Extension of exclusivity period for new qualified infectious disease products. Utilizing real world evidence. Regulation of certain nonprescription drugs that are marketed without an approved drug application. Expedited approval of drugs for serious or life-threatening diseases or conditions. Accelerated approval of priority counter-	360aa. 360bb. 360cc. 360dd. 360ee. 360ff. 360ff-1. PART 360hh. 360jj. 360kk. 360ll. 360mm. 360oo. 360pp. 360qq.	B—Drugs for Rare Diseases or Conditions Recommendations for investigations of drugs for rare diseases or conditions. Designation of drugs for rare diseases or conditions. Protection for drugs for rare diseases or conditions. Open protocols for investigations of drugs for rare diseases or conditions. Grants and contracts for development of drugs for rare diseases and conditions. Priority review to encourage treatments for rare pediatric diseases. Targeted drugs for rare diseases. C—ELECTRONIC PRODUCT RADIATION CONTROL Definitions. Program of control. Studies by Secretary. Performance standards for electronic products. Notification of defects in and repair or replacement of electronic products. Imports. Inspection, records, and reports. Prohibited acts. Enforcement. Repealed.
353a-1. 353b. 353c. 353d. 354. 355. 355-2. 355-2. 355a. 355b. 355c. 355c-1. 355d. 355e. 355f. 355f. 355f. 355f.	Pharmacy compounding. Enhanced communication. Outsourcing facilities. Prereview of television advertisements. Process to update labeling for certain generic drugs. Veterinary feed directive drugs. New drugs. Risk evaluation and mitigation strategies. Actions for delays of generic drugs and biosimilar biological products. Pediatric studies of drugs. Adverse-event reporting. Research into pediatric uses for drugs and biological products. Report. Internal committee for review of pediatric plans, assessments, deferrals, deferral extensions, and waivers. Pharmaceutical security. Extension of exclusivity period for new qualified infectious disease products. Utilizing real world evidence. Regulation of certain nonprescription drugs that are marketed without an approved drug application. Expedited approval of drugs for serious or life-threatening diseases or conditions. Accelerated approval of priority countermeasures.	360aa. 360bb. 360cc. 360dd. 360ee. 360ff. 360ff-1. PART 360hh. 360jj. 360kk. 360ll. 360pn. 360pp. 360qq. 360rr.	B—Drugs for Rare Diseases or Conditions Recommendations for investigations of drugs for rare diseases or conditions. Designation of drugs for rare diseases or conditions. Protection for drugs for rare diseases or conditions. Open protocols for investigations of drugs for rare diseases or conditions. Grants and contracts for development of drugs for rare diseases and conditions. Priority review to encourage treatments for rare pediatric diseases. Targeted drugs for rare diseases. C—ELECTRONIC PRODUCT RADIATION CONTROL Definitions. Program of control. Studies by Secretary. Performance standards for electronic products. Notification of defects in and repair or replacement of electronic products. Imports. Inspection, records, and reports. Prohibited acts. Enforcement. Repealed. Federal-State cooperation.
353a-1. 353b. 353c. 353d. 354. 355. 355-1. 355-2. 355a. 355b. 355c. 355c-1. 355d. 355e. 355f. 355g. 355h. 356. 356.	Pharmacy compounding. Enhanced communication. Outsourcing facilities. Prereview of television advertisements. Process to update labeling for certain generic drugs. Veterinary feed directive drugs. New drugs. Risk evaluation and mitigation strategies. Actions for delays of generic drugs and biosimilar biological products. Pediatric studies of drugs. Adverse-event reporting. Research into pediatric uses for drugs and biological products. Report. Internal committee for review of pediatric plans, assessments, deferrals, deferral extensions, and waivers. Pharmaceutical security. Extension of exclusivity period for new qualified infectious disease products. Utilizing real world evidence. Regulation of certain nonprescription drugs that are marketed without an approved drug application. Expedited approval of drugs for serious or life-threatening diseases or conditions. Accelerated approval of priority countermeasures. Manufacturing changes.	360aa. 360bb. 360cc. 360dd. 360ee. 360ff. 360ff-1. PART 360hh. 360jj. 360kk. 360ll. 360pn. 360oo. 360pp. 360qq. 360rr. 360ss.	B—Drugs for Rare Diseases or Conditions Recommendations for investigations of drugs for rare diseases or conditions. Designation of drugs for rare diseases or conditions. Protection for drugs for rare diseases or conditions. Open protocols for investigations of drugs for rare diseases or conditions. Grants and contracts for development of drugs for rare diseases and conditions. Priority review to encourage treatments for rare pediatric diseases. Targeted drugs for rare diseases. C—ELECTRONIC PRODUCT RADIATION CONTROL Definitions. Program of control. Studies by Secretary. Performance standards for electronic products. Notification of defects in and repair or replacement of electronic products. Imports. Inspection, records, and reports. Prohibited acts. Enforcement. Repealed. Federal-State cooperation. State standards.
353a-1. 353b. 353c. 353d. 354. 355. 355-1. 355-2. 355a. 355b. 355c. 355c. 355c. 355e. 355f. 355f. 356. 356. 356. 356.	Pharmacy compounding. Enhanced communication. Outsourcing facilities. Prereview of television advertisements. Process to update labeling for certain generic drugs. Veterinary feed directive drugs. New drugs. Risk evaluation and mitigation strategies. Actions for delays of generic drugs and biosimilar biological products. Pediatric studies of drugs. Adverse-event reporting. Research into pediatric uses for drugs and biological products. Report. Internal committee for review of pediatric plans, assessments, deferrals, deferral extensions, and waivers. Pharmaceutical security. Extension of exclusivity period for new qualified infectious disease products. Utilizing real world evidence. Regulation of certain nonprescription drugs that are marketed without an approved drug application. Expedited approval of drugs for serious or life-threatening diseases or conditions. Accelerated approval of priority countermeasures. Manufacturing changes. Reports of postmarketing studies.	360aa. 360bb. 360cc. 360dd. 360ee. 360ff. 360ff-1. PART 360hh. 360jj. 360kk. 360ll. 360pn. 360oo. 360pp. 360qq. 360rr. 360ss.	B—Drugs for Rare Diseases or Conditions Recommendations for investigations of drugs for rare diseases or conditions. Designation of drugs for rare diseases or conditions. Protection for drugs for rare diseases or conditions. Open protocols for investigations of drugs for rare diseases or conditions. Grants and contracts for development of drugs for rare diseases and conditions. Priority review to encourage treatments for rare pediatric diseases. Targeted drugs for rare diseases. C—ELECTRONIC PRODUCT RADIATION CONTROL Definitions. Program of control. Studies by Secretary. Performance standards for electronic products. Notification of defects in and repair or replacement of electronic products. Imports. Inspection, records, and reports. Prohibited acts. Enforcement. Repealed. Federal-State cooperation.
353a-1. 353b. 353c. 353d. 354. 355. 355-1. 355-2. 355a. 355b. 355c. 355c-1. 355d. 355e. 355f. 355g. 355h. 356. 356.	Pharmacy compounding. Enhanced communication. Outsourcing facilities. Prereview of television advertisements. Process to update labeling for certain generic drugs. Veterinary feed directive drugs. New drugs. Risk evaluation and mitigation strategies. Actions for delays of generic drugs and biosimilar biological products. Pediatric studies of drugs. Adverse-event reporting. Research into pediatric uses for drugs and biological products. Report. Internal committee for review of pediatric plans, assessments, deferrals, deferral extensions, and waivers. Pharmaceutical security. Extension of exclusivity period for new qualified infectious disease products. Utilizing real world evidence. Regulation of certain nonprescription drugs that are marketed without an approved drug application. Expedited approval of drugs for serious or life-threatening diseases or conditions. Accelerated approval of priority countermeasures. Manufacturing changes.	360aa. 360bb. 360cc. 360dd. 360ee. 360ff. 360ff-1. PART 360hh. 360ii. 360jj. 360kk. 360ll. 360mm. 360nn. 360pp. 360qq. 360rr. 360ss. PART I	B—Drugs for Rare Diseases or Conditions Recommendations for investigations of drugs for rare diseases or conditions. Designation of drugs for rare diseases or conditions. Protection for drugs for rare diseases or conditions. Open protocols for investigations of drugs for rare diseases or conditions. Grants and contracts for development of drugs for rare diseases and conditions. Priority review to encourage treatments for rare pediatric diseases. Targeted drugs for rare diseases. C—ELECTRONIC PRODUCT RADIATION CONTROL Definitions. Program of control. Studies by Secretary. Performance standards for electronic products. Notification of defects in and repair or replacement of electronic products. Imports. Inspection, records, and reports. Prohibited acts. Enforcement. Repealed. Federal-State cooperation. State standards.